2018 Genitourinary Cancers Symposium going on Feb 8-10. In addition to the abstracts being presented regarding enzalutamide and apalutamide, there will be much additional discussion of the various facets of prostate cancer. This conference does seem to also offer trials in progress presentations. I did a quick key word searcha and the only bromodomain related hit was for a GSK presentation on their combo study in patients with mCRPC. I didn't see any abstracts for Zenith or Gilead on the list, though I may have missed them. 

A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.